

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## NICE guidelines

### Equality impact assessment

#### **Venous thromboembolism: reducing the risk**

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

#### **1.0 Scope: before consultation (To be completed by the developer and submitted with the draft scope for consultation)**

1.1 Have any potential equality issues been identified during the development of the draft scope, before consultation, and, if so, what are they?

It was noted that heparin is derived from porcine origin so if recommended we will need to ensure that patients with religious or personal beliefs about the use of animal derived products are given the opportunity to express their concerns and to receive information about alternative options.

1.2 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee? For example, if population groups, treatments or settings are excluded from the scope, are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

The guideline does not cover children and young people (under 16). Stakeholders agreed with this as it is rare for this group to acquire VTE and need prophylaxis. The other areas that are not covered in this scope are addressed by other guidance.

Completed by Developer: Norma O'Flynn

Date: 1/12/15

Approved by NICE quality assurance lead: Sarah Willett

Date 11/12/2015